Lumretuzumab
Lumretuzumab
Lumretuzumab (pronounced loom-reh-too-zoo-mab) is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets and attaches to the HER3 (human epidermal growth factor receptor 3) protein on the surface of cancer cells, blocking the signals that tell the cancer cells to grow and divide.
Etymology
The name "Lumretuzumab" is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, while "lum-" is a prefix used for substances related to the immune system.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. Lumretuzumab is a monoclonal antibody.
- HER3: A protein found on the surface of some cells and in some tumors. Lumretuzumab targets this protein.
- Biological therapy: Treatment to stimulate or restore the ability of the immune system to fight cancer. Lumretuzumab is a type of biological therapy.
- Cancer: A term for diseases in which abnormal cells divide without control and can invade nearby tissues. Lumretuzumab is used in the treatment of cancer.
External links
- Medical encyclopedia article on Lumretuzumab
- Wikipedia's article - Lumretuzumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski